Abstract
Objective: To investigate whether adjuvant chemotherapeutic treatment in patients with operated endometrial cancer in early stages has benefits. Methods: Identification of the studies in electronic databases: MEDLINE, EMBASE, COCHRANE and LILACS. Results: A total of 560 patients were analyzed. Of these, 168 were submitted to chemotherapy, 84 underwent chemotherapy and radiotherapy and 308 of the comparison group, being 72 with radiotherapy and 236 receiving no adjuvant treatment. There was no statistically significant difference between the use of adjuvant chemotherapy for endometrial cancer in early stages and overall survival in five years (RD = 0.19 with 95% CI, -0.39 to 0.02). In the meta-analysis, 3 studies showed greater overall survival in five years with the use of chemotherapy when compared to the control group without chemotherapy and in 2 studies there was no difference between groups. Regarding recurrence, the use of adjuvant chemotherapy (RD = 0.14 with 95% CI, -0.33 to 0.06) was not significant. Conclusion: It was not possible to define benefit or harm with adjuvant chemotherapy in early endometrial cancer in relation to global survival and recurrence.